PL3045471T3 - Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację - Google Patents

Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Info

Publication number
PL3045471T3
PL3045471T3 PL16158141T PL16158141T PL3045471T3 PL 3045471 T3 PL3045471 T3 PL 3045471T3 PL 16158141 T PL16158141 T PL 16158141T PL 16158141 T PL16158141 T PL 16158141T PL 3045471 T3 PL3045471 T3 PL 3045471T3
Authority
PL
Poland
Prior art keywords
alpha
sialylation
recombinant fsh
fsh containing
containing alpha
Prior art date
Application number
PL16158141T
Other languages
English (en)
Polish (pl)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3045471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL3045471T3 publication Critical patent/PL3045471T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16158141T 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację PL3045471T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP16158141.8A EP3045471B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
PL3045471T3 true PL3045471T3 (pl) 2017-10-31

Family

ID=39717519

Family Applications (6)

Application Number Title Priority Date Filing Date
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL16158141T PL3045471T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Country Status (29)

Country Link
US (6) US8951967B2 (enExample)
EP (7) EP3144318B1 (enExample)
JP (7) JP2011519359A (enExample)
KR (5) KR20170110741A (enExample)
CN (3) CN102066414A (enExample)
AR (1) AR071479A1 (enExample)
AU (5) AU2009237479B2 (enExample)
BR (1) BRPI0910461B8 (enExample)
CA (1) CA2725257A1 (enExample)
CY (1) CY1115413T1 (enExample)
DK (6) DK3045471T3 (enExample)
ES (5) ES2610277T3 (enExample)
FI (4) FI3098234T3 (enExample)
FR (3) FR17C1020I2 (enExample)
HR (5) HRP20241187T1 (enExample)
HU (9) HUE068565T2 (enExample)
IL (2) IL208538A (enExample)
LT (8) LT3045471T (enExample)
MX (3) MX355457B (enExample)
NO (4) NO2017025I1 (enExample)
NZ (1) NZ588381A (enExample)
PL (6) PL2808340T3 (enExample)
PT (6) PT2268666E (enExample)
RU (3) RU2537268C2 (enExample)
SA (1) SA109300228B1 (enExample)
SI (6) SI2808340T1 (enExample)
TW (1) TWI488640B (enExample)
WO (1) WO2009127826A1 (enExample)
ZA (1) ZA201007373B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CN103619358B (zh) * 2011-03-31 2017-02-15 辉凌公司 药物制剂
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
PL3662925T3 (pl) 2015-04-17 2021-10-25 Ferring B.V. Kompozycja zawierająca FSH do leczenia niepłodności
JP6845813B2 (ja) 2015-06-26 2021-03-24 フェリング ベスローテン フェンノートシャップ 精製および／またはウイルス不活性化の方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
DK3973982T3 (da) 2017-09-01 2024-09-23 Ferring Bv Sammensætning til kontrolleret ovariestimulation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
JP2025511129A (ja) 2022-04-01 2025-04-15 フェリング ベスローテン フェンノートシャップ 不妊症の治療のための混合プロトコル
US20250333466A1 (en) 2022-05-26 2025-10-30 Ferring B.V. Compositions and methods for treatment of infertility in males
US20250367262A1 (en) 2022-07-08 2025-12-04 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
BR0010709B1 (pt) 1999-05-07 2011-11-29 uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
DE60212425T2 (de) * 2001-10-22 2006-11-09 Applied Research Systems Ars Holding N.V. Fsh-zusammensetzungen mit hohem sialylierungsgrad und deren verwendung zur herstellung von arzneimitteln
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
CN100547069C (zh) 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
EP2600809B1 (en) 2010-08-03 2015-02-25 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
RU2682270C2 (ru) 2019-03-18
TW200948378A (en) 2009-12-01
LTPA2025525I1 (enExample) 2025-07-25
PT3144318T (pt) 2020-11-04
EP3098234B1 (en) 2024-07-31
LT4015527T (lt) 2025-04-10
AU2017225020B2 (en) 2019-11-14
NZ588381A (en) 2012-05-25
BRPI0910461A2 (pt) 2018-03-27
EP2268666B1 (en) 2014-03-12
PT4015527T (pt) 2025-04-10
PT2808340T (pt) 2016-11-21
PT3098234T (pt) 2024-10-21
US20210332099A1 (en) 2021-10-28
CN105906703A (zh) 2016-08-31
HUS1700025I1 (hu) 2017-06-28
FR25C1003I1 (fr) 2025-02-28
RU2010141908A (ru) 2012-05-27
LTPA2017018I1 (lt) 2017-06-26
PT2268666E (pt) 2014-06-25
NO2025032I1 (no) 2025-07-14
EP2268666A1 (en) 2011-01-05
HUE030652T2 (en) 2017-05-29
JP2018021037A (ja) 2018-02-08
KR20160056960A (ko) 2016-05-20
JP2024038000A (ja) 2024-03-19
LT3045471T (lt) 2017-07-10
EP3098234A1 (en) 2016-11-30
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
SI3098234T1 (sl) 2024-10-30
US20160347811A1 (en) 2016-12-01
AU2009237479A1 (en) 2009-10-22
ES2629392T3 (es) 2017-08-09
BRPI0910461B8 (pt) 2021-05-25
FR17C1020I1 (enExample) 2020-04-10
HUE033830T2 (en) 2018-01-29
LTPA2017029I1 (lt) 2017-10-10
PL2808340T3 (pl) 2017-02-28
HUS1700036I1 (hu) 2017-10-30
KR20190092608A (ko) 2019-08-07
CN105906702A (zh) 2016-08-31
KR20110005863A (ko) 2011-01-19
LT3098234T (lt) 2024-09-10
EP4015527A1 (en) 2022-06-22
ES2468318T3 (es) 2014-06-16
FIC20250003I1 (fi) 2025-01-15
AU2009237479B2 (en) 2014-05-15
US20180079794A1 (en) 2018-03-22
FI3098234T3 (fi) 2024-10-31
HUS2500029I1 (hu) 2025-07-28
HK1146284A1 (en) 2011-05-20
PL3098234T3 (pl) 2025-01-07
EP2722339A1 (en) 2014-04-23
DK2808340T3 (en) 2016-12-05
DK3098234T3 (da) 2024-10-21
CA2725257A1 (en) 2009-10-22
FR17C1020I2 (fr) 2020-04-10
DK3045471T3 (en) 2017-06-26
JP6762916B2 (ja) 2020-09-30
EP3045471B1 (en) 2017-03-29
SI2268666T1 (sl) 2014-07-31
SI4015527T1 (sl) 2025-05-30
AU2014203277B2 (en) 2017-04-06
RU2745557C1 (ru) 2021-03-29
JP2022031652A (ja) 2022-02-22
AU2017225020A1 (en) 2017-09-28
JP6486310B2 (ja) 2019-03-20
JP7316905B2 (ja) 2023-07-28
LT2808340T (lt) 2016-11-10
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
NO2025006I1 (no) 2025-01-16
AU2014203277C1 (en) 2017-07-27
PL3144318T3 (pl) 2021-02-08
SI3144318T1 (sl) 2020-12-31
EP2808340B1 (en) 2016-08-17
AU2017204259A1 (en) 2017-07-20
US9771407B2 (en) 2017-09-26
RU2745557C3 (ru) 2021-12-10
HRP20161520T1 (hr) 2016-12-30
PL2268666T3 (pl) 2014-08-29
NO2017050I1 (no) 2017-09-28
ES2989729T3 (es) 2024-11-27
EP2808340A1 (en) 2014-12-03
AR071479A1 (es) 2010-06-23
BRPI0910461B1 (pt) 2021-02-23
SA109300228B1 (ar) 2014-04-08
IL230571A (en) 2015-11-30
WO2009127826A1 (en) 2009-10-22
BRPI0910461A8 (pt) 2018-10-16
DK4015527T3 (da) 2025-04-14
PT3045471T (pt) 2017-06-14
KR20170110741A (ko) 2017-10-11
JP2020040956A (ja) 2020-03-19
HUS2500008I1 (hu) 2025-02-28
SI2808340T1 (sl) 2016-12-30
US11952407B2 (en) 2024-04-09
AU2017204258B2 (en) 2017-08-17
EP4015527B1 (en) 2025-01-22
US20150065695A1 (en) 2015-03-05
AU2017204259B2 (en) 2017-08-17
CN102066414A (zh) 2011-05-18
RU2014141994A (ru) 2016-05-10
DK3144318T3 (da) 2020-12-07
HRP20170958T1 (hr) 2017-09-22
HUE068565T2 (hu) 2025-01-28
EP3045471A1 (en) 2016-07-20
HUS1700024I1 (hu) 2017-06-28
SI3045471T1 (sl) 2017-07-31
HRP20250313T1 (hr) 2025-05-09
HUE030652T4 (en) 2017-09-28
RU2014141994A3 (enExample) 2018-05-28
CY1115413T1 (el) 2017-01-04
US20240327487A1 (en) 2024-10-03
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
ES3023526T3 (en) 2025-06-02
IL208538A (en) 2014-03-31
LTPA2025505I1 (enExample) 2025-02-10
RU2537268C2 (ru) 2014-12-27
IL208538A0 (en) 2010-12-30
US10995128B2 (en) 2021-05-04
JP2015120696A (ja) 2015-07-02
MX355457B (es) 2018-04-19
US8951967B2 (en) 2015-02-10
TWI488640B (zh) 2015-06-21
EP3144318A1 (en) 2017-03-22
US20110105398A1 (en) 2011-05-05
JP2011519359A (ja) 2011-07-07
JP2017060476A (ja) 2017-03-30
EP3144318B1 (en) 2020-09-23
AU2014203277A1 (en) 2014-07-24
US9546204B2 (en) 2017-01-17
ZA201007373B (en) 2011-06-29
DK2268666T3 (da) 2014-05-12
KR101622944B1 (ko) 2016-05-23
FR25C1025I1 (fr) 2025-09-19
NO2017025I1 (no) 2017-06-06
KR102108377B1 (ko) 2020-05-08
HUE071059T2 (hu) 2025-07-28
KR20180095140A (ko) 2018-08-24
FI4015527T3 (fi) 2025-04-29
AU2017204258A1 (en) 2017-07-20
FIC20250025I1 (fi) 2025-07-11
HK1199039A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
HRP20170958T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju
UY33125A (es) Diaza-espiro-[5,5]-undecanos
IL208873A0 (en) Novel n-(2-amino-phenyl)-acrylamides
FI20085362A0 (fi) Kahmari
BRPI1014211A2 (pt) "composição."
LT3144318T (lt) Rekombinantinis fsh, įskaitant alfa-2,3- ir alfa-2,6-sialilinimą
CN300893078S (zh) 瓶子(1)
TH105749B (th) ไทรซับสทิทิวเทด 1,2,4 ไทรแอโซล
FI20080380A0 (fi) Liikeanalysaattori
FI7964U1 (fi) Liitoskappale
FI8353U1 (fi) Liitoskappale
GB0705503D0 (en) The buffer
CN301237260S (zh) 瓶贴(消毒液)